CASPA's Early Intervention Young Mothers Program addresses the high birth rates among vulnerable young mothers who have an out-of-home-care experience, including Indigenous communities. Our Shared Living Accommodation Facility combined with our holistic care approach offers a nurturing environment that supports parenting skills, financial independence, and emotional healing. We seek a $4-$5 million concessional loan or a guarantee to build a shared living facility in rural NSW, empowering young mothers and breaking the cycle of disadvantage.
Investors will find CASPA's initiative attractive due to its proven impact and potential for revenue generation, as a concessional loan at 6% offers security. As an alternative solution, our future partner can act as a guarantor for CASPA, which would enable us to secure a loan from our bank more easily.
Key Investment Highlights
The impacts of this initiative will be profound. By providing a safe and supportive space, we can help break the cycle of disadvantage that often traps young mothers and their children.
The skills they gain will empower them to forge a path toward financial independence, while their children will benefit from a stable, loving environment that fosters growth and development.
Ultimately, we will not only transform the lives of these young mothers but also create a ripple effect that benefits future generations, contributing to a healthier, more resilient community. This is not just a facility; it is a foundation for a brighter future—a place where dreams can be realised and potential unlocked.
Investment Summary
CASPA is actively seeking a concessional loan of $4 – $5 million to support its mission of empowering vulnerable young mothers. With an annual interest rate of 5% over a 10-year term, such loan is appealing to impact investors translating to 120 total payments, at approximately $50K monthly on a $4.6m loan. This concessional financial arrangement also ensures that CASPA can effectively fund its programs while maintaining a sustainable repayment plan. Alternatively, our future partner can act as a guarantor for CASPA, which would enable us to secure a loan from our bank more easily. In return for your guarantee, we offer accomplishment of performance-based milestones, committing to place 12 young mothers with newborns into stable environments whilst developing their parenting and life skills training. Regular progress reports will keep you informed about key metrics such as improved parenting skills and financial independence. By investing in CASPA, you are not just securing a stable return; you are contributing to a meaningful cause that enhances the lives of young mothers and their children. This initiative exemplifies a blend of social responsibility and financial opportunity, making it an attractive proposition. Your partnership can create lasting impacts, fostering sustainable change in the community and transforming lives for generations to come.
Visit Website
Join us to empower the future of Climate Technology in SEA – Led by an experienced female General Partner, our fund invests in leading startups focused on climate mitigation and adaptation. We back bold founders tackling climate change with scalable solutions, delivering both impact and financial returns.
Key Investment Highlights
Strong team
led by a female GP with 20+ years of investing experience, along with two partners with energy transition background
Established track record in climate investing
established a pro-forma track record of 4x MOIC across 13 investments
Backed by strong global investors
we have been backed by IFC and follow their reporting framework. Our climate fund is anchored by Australia Development Investment
Investment Summary
Fund details
Governing Law: Singapore
Fund Size: $50M (hard cap at $100M)
First close: 1H 2025
Final close: Within 12 months of First Close
Term: 10 + 2 years
Investment Period: 5 years
Minimum commitment: $2M
Fund lawyers: King & Wood Mallesons
Agent: Vistra
Investment objectives
Stage: Multistage
Geographic focus: 50% Indonesia, 50% startups in emerging Asia entering Indonesia
Portfolio: 15 companies
Target ownership: 15-20% ownership level
Sub-sector focus: renewable energy, electric mobility, energy efficiency, climate smart agriculture and waste & circularity
Structure
Management fee: 2.5% over committed capital during investment period, 1.5% over invested capital thereafter
Carried interest: 20%
View PDF
With FDA Breakthrough Designation for its flagship product, Minder, Epiminder's expectation is for FDA approval by mid-April 2025 and an ASX listing this calendar year, subject to market conditions.
Key Investment Highlights
Breakthrough designated product
with anticipated FDA approval as early as mid-April 2025.
Tackling a US$16bn p.a. cost burden to the U.S.
with an initial target segment generating US$1bn p.a.
Blue chip founding investors and commercial partners
including Cochlear (COH.ASX), University of Melbourne, St Vincent's Hospitals, and the Bionics Institute.
Investment Summary
Epiminder is a pioneering medical technology company developing an innovative solution for epilepsy monitoring. Through groundbreaking trials, Minder has demonstrated the ability to overcome a major challenge in epilepsy care – long-term identification and monitoring of epileptic syndromes for both physicians and patients.
Minder enables [superior / more promising] seizure detection compared to the current 'gold standard', helping neurologists optimise treatment plans, reduce hospital visits, and improve patients' quality of life. Additionally, Epiminder's technology may also have potential applications beyond epilepsy.
Epiminder is positioned to be the first to capitalise on a substantial U.S. market opportunity, initially targeting a segment generating ~US$1bn in annual revenue. The company has secured American Medical Association (AMA) approval for CPT codes for Minder, with U.S. payors recognising the need for accurate seizure monitoring. Approximately 40 leading epilepsy centres – including Harvard Medical Teaching Hospital, Stanford Medicine, and Yale School of Medicine – have expressed interest in participating in upcoming DETECT trials, reinforcing momentum for payor support and physician adoption.
The company presents an opportunity to invest in an exceptional founding team: proven world leading manufacturer, top class research and clinical expertise in Cochlear Ltd (COH.ASX), the University of Melbourne, St Vincent's Hospitals, and the Bionics Institute.
Visit Website
CCREAT is ultimately seeking a long-term capital partner to help deliver its solar and battery project pipeline and continue growing from $30M (current) to >$200M over the three years. Our immediate capital raise target is for $25.5M over 12 months to complete committed projects in NSW, SA and WA.
Key Investment Highlights
Provides unitholders with low-risk, predictable returns through a diverse and growing portfolio of operating renewable energy assets.
Directly and demonstrably offsets CO2e from grid-supplied traditional electricity generation sources.
Supports small to medium-sized Australian companies with low-cost, emission-free electricity without the risk of investing in new, non-core assets.
Investment Summary
CCREAT owns four operating solar farms and one land holding across Australia valued at $30M, and retains a first right of investment on Climate Capital's >$200M project pipeline. Climate Capital originates projects that align with CCREAT's investment criteria (10+ years offtake, min 80% contracted volume, credible counterparty, average 10-12% unlevered IRR), and under an asset management agreement, builds and operates these assets to provide unitholders with portfolio target investment returns in capital growth of 5-10% plus distribution yields of 6-8%.
Over the past five years, projects had been sized (<5MW or ~$8M) to accommodate investor expectations on a low-risk, quick deployment, behind-the-meter strategy at industrial locations with grid access. Today, Climate Capital's pipeline contains a range of project sizes and complexities, however all still aligning with the investment principles of long-term, predictable returns with credible counterparties.
An investment in CCREAT provides the immediate benefits of participation in a diverse, operating portfolio generating cashflow, access to over $200M of new projects over the next three years, and an experienced, dedicated team supported by strong industry colleagues, ready to deliver significant long-term value through renewable energy and storage assets across the country.
View PDF
Cordis Asset Management generates investment returns via exposure to listed medical technology companies researching, developing, and marketing critical technology for now and the future. By investing in this critical segment of the healthcare sector, we offer investors the opportunity to invest with genuine impact by promoting technology that saves, prolongs and improves life all across the planet.
The Fund offers exposure to a high growth MedTech portfolio that is
Key Investment Highlights
Underwritten by the insatiable demand for healthcare and funnelled into the select few companies with regulatory approval to market and manufacture these devices,
Largely decoupled from macro environment trends, aiming to deliver returns throughout the complete economic cycle, and
Ultimately providing significant positive impact, by investing in technology that is saving, prolonging and improving lives
Investment Summary
We manage a single investment portfolio to capitalize on the ageing population and the medical technology revolution which we believe will result in sustainable outperformance. The global population is ageing, and advanced age is the number one risk factor for almost all health conditions. However, advancements in medical technology now allow for effective interventions well into later life, which we believe will result in sustainable positive returns. We aim to capitalize on this trend by identifying innovative medical technology companies that address these unique challenges and opportunities.
The Cordis Global Medical Technology Fund is a fund designed to complement a broad range of equity strategies as a satellite investment to a core portfolio. It is available on multiple platforms and has been rated 4.25 Stars (high investment grade) by SQM.
Visit Website
Dirty Clean Food ("DCF") is Australia's leading consumer brand for regenerative agriculture and ethical food, growing sales at a 50%+ CAGR since inception Based in Perth, DCF's annual revenue is A$15 million with breakeven expected by June 2025.
DCF is launching a Series A funding round of up to A$1.5 million in growth capital for geographic and product expansion.
Key Investment Highlights
Proven Concept
DCF has generated $50MM in cumulative revenue to 50,000+ customers in Australia, Hong Kong, Singapore and Vietnam.
Scalable Model
DCF scales with proprietary processes and technology, generating mid double-digit incremental free cash flow margins.
Massive Impact
DCF supports 25 family farmers and 30,000 hectares of land under regenerative agriculture practices.
Investment Summary
Dirty Clean Food ("DCF") has disrupted food in Western Australia with an innovative consumer brand dedicated to regenerative agriculture and ethical food. With annualised sales of A$15 million, DCF is available in hundreds of groceries, is chosen by 40% of The WA Good Food Guide's Top 100 restaurants, and is available for next-day home delivery via www.dirtycleanfood.com.au.
The brand is built to scale. It's a premium offer underpinned by the thesis that today's consumers will pay a fair price for delicious food they trust has a positive impact on people and planet.
The results speak for themselves. Since inception, sales have risen at a 50% CAGR, with breakeven expected in June 2025. The export business has grown from nil last year to 10% of revenues in FY2025, proving our brand resonates globally.
With the concept proven in Perth, DCF is launching a Series A growth funding round of up to A$1.5 million to accelerate new market expansion.
An investment in DCF solves a critical problem in the modern food system. Consumers want access to regen produce but are sceptical of "sustainable" marketing from large incumbent food companies. The answer – and opportunity –is Dirty Clean Food.
Visit Website
Ferronova is seeking new investors to co-invest with existing shareholders in a $6m+ equity round. The investment will be used to prepare Ferronova for a US registration study in gastric and oesophageal cancer, indications with low survival rates and a significant unmet need for minimally invasive image guided treatment and surgery.
Key Investment Highlights
High impact investment
by addressing an ignored unmet need in complex solid tumour cancers with a novel nanoparticle platform protected by 7 patent families
Proven clinical stage first pipeline product
with 60 clinical trial patients to date.
Strong strategic investor
who provides access to a global distribution channel
Investment Summary
Gastric and oesophageal cancers have poor outcomes, due to cancer spreading from a primary location to lymph nodes that are found anywhere from the neck to the abdomen. Current imaging methods (CT and PET) are unable to detect nearly all cancers in these lymph nodes and as a result surgery is extensive, with complication rates of 59% in oesophageal cancer and 41% in gastric cancer. Leaving behind lymph nodes with cancer is devastating for patients, with 3-year survival rates in Australia only 43% for localised oesophageal cancer and 28% if cancer is found in lymph nodes.
Ferronova first program, FerroTrace, is designed to resolve this issue by enabling clinicians to identify the lymph nodes where cancer spreads first with Magnetic Resonance Imaging (MRI). This enables the clinical team to plan treatment and surgery, in some cases replacing surgery with sampling of these critical nodes. If these draining nodes are clear of cancer, then surgery can be minimised or eliminated.
FerroTrace has been evaluated in two completed clinical trials totalling 30 patients with a 100% negative predictive value. A 60-patient gastric and oesophageal cancer trial is ongoing at five centres in Australia, with enrolment expected to complete in 2025.
Visit Website
Fremantle Seaweed growing the red seaweed, Asparagopsis, demonstrated by CSIRO to reduce cattle methane emissions by 80%.
After demonstrating proof of concept, we are ready to accelerate production to introduce our climate solution to market and support the growth of lower emissions beef and dairy. We are raising seed capital from investors who share our mission of moving the dial on climate change.
Key Investment Highlights
We are Australia's first and only operator growing Asparagopsis solely on a marine lease – which is lower cost than other production methods
With a sustainable business model that produces a demonstrated climate solution, social and environmental impact is at heart of everything we do
Our raise provides a large-scale deal ($7m) to deliver strong climate impact with patient, long-term returns.
Investment Summary
Emissions from enteric fermentation (i.e., methane from livestock's guts) make up 5% of global GHG emissions – this is greater than aviation, rail transport and shipping combined! With methane being 28x more potent than carbon, the climate imperative to work with farmers and help reduce cattle methane emissions is substantial.
Fremantle Seaweed are accelerating the deployment of a leading solution to this challenge by cultivating and producing Asparagopsis feed supplements for cattle.
We are growing Asparagopsis where seaweed grows best: in the ocean. Our advantageous marine lease is in the 'goldilocks zone' for its cultivation, placing us in the prime position to become Australia's leading Asparagopsis producers
In 2024, we solved for the biggest challenge to commercialisation: successfully growing out trials of Asparagopsis cultivated tetraspores on a marine lease – an Australian first!
As we now look to scale, we anticipate that we could drive the abatement of 620,244 tCO2e- per year.
We are looking for seed investors to join us in our mission by providing both patient capital – through equity or debt arrangements – and strategic advice to support us scale our operations and expand our commercial partnerships.
Visit Website
HB Biotechnology offers wholesale investors access to a highly curated portfolio of listed, global biotechnology stocks, delivering attractive financial returns with low correlation to equity markets. With deep scientific expertise and a proven track record of outperformance, HB Biotechnology adopts a focused and strategic approach to investing in breakthrough medical advancements.
Key Investment Highlights
HB Biotechnology has a long history of outperformance, historically outperforming its index by greater than 10% p.a., after fees
Investment in biotechnology offers high risk adjusted returns with very low correlation to overall listed markets, making it ideal for portfolio diversification
Significant structural tailwinds exist, driving continued innovation and development in biotechnology
Investment Summary
Investing in Biotechnology offers strong financial returns with low correlation to broader equity markets, making it ideal for portfolio diversification. As aging populations fuel demand for novel therapies, biotech delivers both profit and purpose—advancing life-saving treatments, extending lifespans, increasing quality of life and combating a wide range of diseases from cancer to rare paediatric disorders. Successfully navigating this complex sector requires specialist investors with deep medical and scientific expertise. HB Biotechnology has a proven long-term track record of outperforming its index, making it a trusted leader in biotech investing.
Visit Website
HeraMED is seeking to identify capital partners to support its planned growth capital round of up to A$5m primarily to accelerate adoption of HeraCARE in the US.
HeraMED is revolutionising maternity care with its AI-powered HeraCARE platform, enhancing pregnancy outcomes through remote monitoring and early intervention. With a clinically validated care model, growing commercial adoption (Broward Health), and a scalable SaaS model, HeraMED is building a strong evidence base while improving maternal health equity globally.
Key Investment Highlights
Proven Market Traction
Active deployments, including Broward Health, drive adoption in the U.S. healthcare system.
Scalable SaaS Model
Recurring revenue potential through hospital subscriptions and payor partnerships.
Impact & Growth
Addresses maternal health disparities while positioning for significant U.S. market expansion.
Investment Summary
HeraMED (ASX: HMD) is transforming maternity care with its AI-powered HeraCARE platform, enabling remote monitoring and early intervention to improve pregnancy outcomes.
Use of Funds:
• Accelerate U.S. hospital adoption, building on success with Broward Health.
• Pursuing discussions and potential partnerships with large and prestigious hospitals across the country
• Expand clinical validation and commercial partnerships to drive healthcare reimbursement pathways.
• Scale sales and support teams to meet growing U.S. demand.
• Advancing relationships with key medical organisations, research, and universities as well as insurance companies
• Developing appropriate partnerships to access non-dilutive government grant funding and potentially benefit from R&D tax concession
Visit Website
Mober is raising Series A funding to accelerate the expansion of its 100% electric vehicle fleet, charging infrastructure, and technology-driven logistics solutions. Investors have the opportunity to be part of the first-mover advantage in sustainable last- and mid-mile delivery, shaping the future of carbon-free logistics in Southeast Asia.
Key Investment Highlights
First-Mover Advantage
As the Philippines' first EV-focused logistics company, Mober is defining the standard for sustainable freight solutions.
Rapid Scalability
With growing partnerships (IKEA, Nestlé, Maersk), we are poised for aggressive regional expansion.
ESG-Driven Growth
Investors gain exposure to the booming green economy with strong government and corporate support for Net Zero commitments.
Investment Summary
Mober is revolutionizing logistics with a fleet of 100% electric delivery vehicles, cutting emissions without increasing costs. With 150 EVs today and a roadmap to 500+ by Q1 2026, we are scaling fast.
Our proprietary Battery Management System (BMS) and Transport Management System (TMS) optimize fleet efficiency, ensuring lower operational costs and higher profitability. Investing in Mober means aligning with a high-growth, impact-driven company that's leading the transition to sustainable logistics in the region. Early investors will benefit from a stake in a rapidly growing sector with strong revenue projections and a significant ESG impact.
Be part of the movement driving Southeast Asia's logistics toward a zero-carbon future.
Visit Website
UGEP is offering a strategic minority investment opportunity of up to $25 million, split between its HoldCo and utility-scale solar projects. This investment will support the company's ambitious growth targets in the Philippines' C&I and utility-scale solar markets, leveraging its strong local presence, operational capacity, and strategic partnerships.
Key Investment Highlights
Proven Track Record
UGEP has 100 MW of operational C&I solar capacity and a robust pipeline of over 300 MW, demonstrating strong execution capabilities.
Strategic Partnerships
Collaborations with industry leaders like Aboitiz Power and Gokongwei Group ensure market access and credibility.
Growth Potential
Targeting 1 GW by 2028, UGEP offers significant scalability in the Philippines' booming renewable energy sector.
Investment Summary
UGEP is seeking a strategic minority investment of up to $25 million, allocated partially into its HoldCo and directly into its utility-scale solar projects. This investment will accelerate the company's growth in the Philippines' commercial, industrial (C&I), and utility-scale solar markets, supporting its goal of achieving 1 GW of renewable energy capacity by 2028.
Investment Highlights:
1. Immediate Impact: Funds will be used to advance utility-scale project development, expand the C&I portfolio, and strengthen operational capabilities.
2. Scalable Growth: With 100 MW of operational C&I capacity, 100 MW of utility-scale projects ready for construction, and an active pipeline of over 300 MW, UGEP offers a clear path to scaling its portfolio.
3. Strategic Partnerships: UGEP's collaborations with Aboitiz Power, Gokongwei Group, and leading financial institutions like DBP and Landbank provide market access, credibility, and financial stability.
Investor Benefits:
– High Growth Potential: The Philippines' renewable energy sector is rapidly expanding, offering significant returns on investment.
– Diversified Portfolio: Exposure to both C&I and utility-scale solar projects mitigates risk and enhances revenue streams.
– Strong Local Presence: UGEP's deep market expertise and established partnerships ensure efficient project execution and long-term success.
This investment opportunity aligns with global sustainability goals while delivering attractive financial returns in a high-growth market.
Visit Website
5North is shifting the trajectory of Australia's social and affordable housing crisis, by bringing the efficiency of robotically assembled prefabricated floors, walls and ceilings to the national housing market. We have $10M+ in commitments to the only raise we are doing, explicit support of State Government and $160M+ in intended orders for 2026.
Key Investment Highlights
Cashflow positive from February 2026
all future growth to be funded out of earnings and debt, massive and increasing demand for our solution
By flat-packing pre-assembled walls, floors and roofing to site (including electrics and plumbing) it can reduce overall delivery time of a home by 50%, thus potentially doubling the completion rate of existing builders
114 man-hours using automation vs 562.5 in traditional builds; 82% less embodied carbon, 30% lower energy use and 90% less waste
Investment Summary
5North are developing a highly automated robotic production factory to disrupt Australia's building industry, and significantly increase the supply of affordable and social homes.
Imagine 12 robots, each the size of an adult giraffe, in a factory 3/4's the size of a soccer field. Instead of 100 workers on the tools, 15 people manage the line, producing precisely engineered modular homes with European levels of acoustic and thermal insulation.
The factory can produce 34 m2 of home every 8 minutes, the equivalent of 972 homes a year, from a single shift of 7.5 hours a day, 48 weeks a year. This can be double or tripled in 1 factory. These can be built up to 6-storeys, delivering high quality at better than market rates.
Led by Wayne Hughes (CEO), 5North have committed $6M+ developing 13 x 3 level townhouses in Adelaide, and to support negotiating agreements with the South Australian Government, Wayne met with the SA Treasurer and Under Treasurer in Cambrideshire, UK.
Here he showed them 78 x 2 level town homes completed in 5 months using our technology, then took the Head of Capital for South Australia's Housing Trust to San Francisco, to see 136 apartments built from dirt to keys in 10 months.
Our modelling details a 3-year payback period for our investors, and conservatively estimated returns of 29%.
View PDF
Unlocking private market potential with Australian Ethical Investment
Join Australian Ethical Investment for an exclusive first look at our soon-to-be-launched private markets opportunity for wholesale investors.
With over $1 billion already invested in private markets, we will soon offer sophisticated investors access to a highly diversified, impact-focused portfolio — built with the same disciplined approach that underpins our Australian Ethical Super Fund.
Key Investment Highlights
$1 billion already invested
built with the same disciplined approach that underpins our Australian Ethical Super Fund.
targeting future-focused thematics — decarbonisation, digitalisation, urbanisation, circular economy and changing demographics
Investment Summary
Designed as a core alternatives holding, this fund will target future-focused thematics — decarbonisation, digitalisation, urbanisation, circular economy and changing demographics — leveraging structural tailwinds to drive both financial returns and meaningful impact.
With a low minimum investment, a targeted 11-13% IRR, and a carefully constructed portfolio of direct, semi-direct and fund investments, this is a rare opportunity to access a thoughtfully curated and diversified private markets strategy.
Join us at the Impact Investment Summit to be among the first to explore this opportunity.
Visit Website
inTruth Technologies is a world first biotech, allowing for real time emotion tracking via consumer wearables.
As a software-driven, hardware-agnostic platform, inTruth seamlessly integrates with existing devices to deliver actionable emotional data, empowering users to make informed decisions.
Key Investment Highlights
strong product-market fit
a patented machine-learning model
key commercial partnerships
Investment Summary
The global wearable market, $170B, presents a vast opportunity. By capturing just 1% of this market, inTruth can generate $500M in ARR. With a strong product-market fit, a patented machine-learning model, and key commercial partnerships, we are on track forge and own a new category in the wearables space and beyond.
We are running active pilots in mental health and motorsports, with profound results, validating inTruth's B2B utility across industries. Investors benefit from our scalable SaaS model, diversified revenue streams, and competitive edge in a category we're defining. Our leadership team, backed by clinical research and AI innovation, is committed to driving long-term growth. Now is the time to join us in transforming emotional health and reshaping the future of human potential.
Visit Website
Reelae is offering a 20% equity stake for a $4 million investment, valuing the company at $20 million post-money. This capital fuels our next phase of growth – scaling Papua New Guinea's first fully digitized national curriculum to serve 100,000+ Flexible Open Distance Education (FODE) students. We are targeting 20,000 licenses in 2025, with operations expanding in Port Moresby and Sydney.
Key Investment Highlights
Transformational First-Mover Advantage
Reelae is the first EdTech company contracted by PNG's Department of Education, spearheading digital education for a nation where 85% of students lack reliable schooling access.
Scalable Market with Government Backing
We've digitized PNG's Grades 7–10 curriculum, with FODE as our launch partner. Expansion to all public schools presents a high-growth, multi-million-dollar opportunity.
Proven Model, Ready to Scale
A successful 2023 pilot, a clear path to 20,000 licenses in 2025, and a 50% profit margin ensure both high impact and strong financial returns.
Investment Summary
The Pacific is at an educational crossroads. In Papua New Guinea alone, nearly one-third of students never complete primary school, and the gap in access to quality education continues to widen. The challenges are immense – limited infrastructure, a severe teacher shortage, and geographical barriers that isolate students from learning opportunities. Without intervention, millions of young people will be left behind, stalling economic growth and deepening social inequality across the region.
Reelae is breaking these barriers.
We have digitized the national curriculum for Grades 7-10, enabling students across PNG – especially in remote and underserved areas – to access structured, high-quality education anytime, anywhere. With $4 million in investment, we will scale this proven model to reach 20,000 students in 2025, with a clear path to nationwide adoption. Our exclusive contract with the PNG Department of Education positions us as the leading EdTech provider in a government-backed transformation of the national education system.
By 2029, revenue from FODE alone is forecast to reach $7.1 million, with a 50% profit margin – before even expanding to public schools and the wider Pacific region. This isn't just a high-growth opportunity; it's an impact-driven, scalable solution to one of the region's most pressing challenges.
Investing in Reelae means unlocking the potential of an entire generation. With our Port Moresby headquarters ensuring deep local engagement and our Sydney office driving global partnerships, we are uniquely positioned to reshape the future of education in PNG and beyond.
This is your opportunity to be at the forefront of transforming education in the Pacific, delivering both financial returns and lasting social impact.
Visit Website
Next Billion's Digital Growth Fund is an impact growth equity fund investing in technology-enabled companies that are delivering essential services – with a focus on financial services and healthcare – across global emerging markets.
Key Investment Highlights
Experienced team:
Investing together in emerging markets technology PE for the last decade
Rapid digitalisation:
High internet penetration, coupled with accelerating demand for essential services, leads to rapid adoption
Opportunities to improve healthcare:
Digital models can vastly improve the quality and affordability of care in the Global South
Investment Summary
• At Next Billion, we are building the impact growth equity specialist focused on emerging markets
• The team built the technology investment platform at IFC / World Bank and has delivered strong financial returns as well as impact at scale in this exact asset class
• Next Billion's second PE fund, the $250M Digital Growth Fund, invests in growth-stage category leaders that are digitalizing financial services and healthcare in Latin America, Africa, and Southeast Asia
• We have held several fund closings and are backed by blue-chip institutional impact investors from the US and Europe. Final close is expected to occur in late 2025
• The Fund will build a portfolio of 15 companies across 5-6 high-impact, high-growth digital business models. We are currently closing on our 3rd investment out of the fund, with an exciting pipeline at the intersection of fintech and digital health
• Standard PE fund terms with 8% hurdle / European waterfall
FivepHusion is raising a minimum of AU$11M and up to AU$20M as a pre-IPO capital raise to prepare its next-generation cancer therapy, Deflexifol®, for registrational clinical trials prior to global market launch. The deal is attractively priced for a ~3-5x investment return via an IPO planned for 2026.
Key Investment Highlights
Deflexifol® has been designed by leading oncologists to meaningfully enhance solid cancer therapy for over six million adults and children globally.
FivepHusion’s development pipeline is technically, clinically and commercially de-risked by developing next-generation innovations of existing technologies.
The investment deal is priced to create a near-term ~3-5x uplift in value prior to a planned IPO in 2026, followed by expected heightened pharma licensing and M&A interest as Deflexifol® approaches commercial launch into billion-dollar market opportunities.
Investment Summary
FivepHusion is a clinically advanced & globally focused private biotechnology company headquartered in NSW, with a purpose to optimise cancer therapy to improve patient treatment outcomes and quality of life. With three early phase clinical trials successfully completed, we are currently preparing for registration trials of our next-generation cancer therapy, Deflexifol®. Our strategic priorities are to optimise treatment for newly diagnosed metastatic colorectal cancer (mCRC, also known as stage 4 bowel cancer), a US$13B market; and paediatric ependymoma, the third most common brain cancer in children. This disease has no approved drugs and is part of the US$1.8B childhood brain cancer market. FivepHusion is planning for commercial launch of Deflexifol® in 2029 with anticipated revenues of >US$1B in 2033.
FivepHusion is raising up to AU$20M now to prepare Deflexifol® for registrational trials in mCRC and paediatric ependymoma. New capital will predominantly fund two Australian clinical trials which are ethics-approved and ready to go, and scale-up pharmaceutical manufacture in Melbourne at Pfizer. Funding will also be used to support engagement with global regulatory agencies, for corporate development and other pipeline opportunities, and for preparations for an IPO designed to fund Deflexifol® through to market registration in 2029.
Visit Website
